Growth Hormone Therapy Denied by Insurance? How to Appeal

Growth hormone (GH) therapy is one of the most heavily restricted treatments in American health insurance. Whether for a child with short stature, an adult with GH deficiency after pituitary surgery, or a patient with an FDA-approved condition like Prader-Willi syndrome or Turner syndrome, the Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization process is extensive and denials are common. This guide covers the major denial scenarios and how to build a successful appeal.

Why Insurers Deny Growth Hormone Therapy

Stimulation test requirements — For adult GH deficiency, insurers almost universally require a formal GH stimulation test before approving therapy. The insulin tolerance test (ITT), glucagon stimulation test (GST), or GHRH-arginine test must show a peak GH response below a threshold (typically <3–5 ng/mL depending on the test and insurer) to confirm deficiency. Denials occur when: the test was not performed, the test used is not accepted by the plan, or results are borderline.

Pediatric short stature criteria not met — For children, insurers often require multiple criteria simultaneously: height ≥2.0–2.5 standard deviations below mean for age/sex, growth velocity below normal for bone age, and documented GH deficiency on stimulation testing. Idiopathic short stature (ISS) approvals are harder to obtain despite FDA approval.

Non-GHD conditions disputed — FDA approves GH for multiple non-GHD conditions: Turner syndrome, Prader-Willi syndrome, SHOX gene deficiency, Noonan syndrome, small for gestational age (SGA) without catch-up growth, and chronic renal insufficiency in children. Insurers may deny based on disputed diagnosis, absent genetic confirmation, or arguable classification of the condition.

Adult GHD not recognized — Some plans take a restrictive view of adult GH deficiency, requiring it to be caused by a hypothalamic-pituitary disorder (post-tumor, post-surgery, post-radiation) and denying GHD in patients without such a structural cause. The Endocrine Society's diagnostic criteria support biochemical GHD diagnosis regardless of cause when stimulation testing is positive.

Cost-based denials — Growth hormone is extremely expensive ($15,000–$50,000/year depending on dose). Some plans impose additional hurdles beyond clinical criteria that effectively function as cost barriers.

Clinical Frameworks Supporting Your Appeal

Endocrine Society Clinical Practice Guideline on GH Deficiency — The Endocrine Society's 2011 guideline (and subsequent updates) defines adult GHD diagnosis as: appropriate clinical features (pituitary disease, childhood GHD, or idiopathic) PLUS biochemical confirmation by GH stimulation test showing peak GH below the assay-specific threshold. The guideline specifies which stimulation tests are acceptable and what peak GH cutoffs are diagnostic.

FDA-Approved Pediatric Indications — GH is FDA-approved for: (1) GH deficiency; (2) chronic renal insufficiency; (3) Turner syndrome; (4) Prader-Willi syndrome; (5) SHOX haploinsufficiency; (6) Noonan syndrome; (7) small for gestational age with failure to catch up; (8) idiopathic short stature (ISS, height ≥2.25 SD below mean). Submit the specific FDA-approved indication matching your child's diagnosis.

IGF-1 and IGFBP-3 Levels — While IGF-1 alone is insufficient to diagnose GHD, low IGF-1 for age (below -2 SD) supports the diagnosis and strengthens an appeal when stimulation testing results are borderline. Include IGF-1 and IGFBP-3 levels with reference ranges in your appeal.

Growth Velocity Documentation — For pediatric appeals, annualized growth velocity below the 25th percentile for bone age is an important supporting criterion. Document height measurements over at least 6 months (preferably 12 months), measured by the same stadiometer by trained personnel, to calculate accurate growth velocity.

Bone Age X-ray — Bone age (left wrist X-ray, Greulich-Pyle method) documents the skeletal maturity relative to chronological age. A significantly delayed bone age is consistent with GH deficiency and is often required by prior authorization forms. Submit the radiology report and interpretation.

Benefits of Treatment in GHD Adults — GH replacement in confirmed adult GHD improves body composition (reduces fat mass, increases lean mass), bone density, lipid profile, quality of life, and exercise capacity. Include the treating endocrinologist's documentation of which of these outcomes the patient is experiencing and why treatment is indicated.

Step-by-Step Appeal Strategy

Step 1: Identify which indication is being denied. Is this a pediatric GHD denial? A pediatric non-GHD indication (Turner, Prader-Willi, ISS)? Or an adult GHD denial? The appeal documents needed differ for each.

Step 2: Confirm stimulation test was performed and results are in the record. For adult GHD, attach the complete stimulation test report — the stimulation agent used, GH values at each time point, and peak GH value. Confirm the assay used is accepted by your plan. Some plans have very specific requirements about which stimulation test is acceptable.

Step 3: Compile all supporting endocrinologic data. IGF-1, IGFBP-3, growth velocity (for pediatric), bone age X-ray, pituitary MRI (if pituitary lesion or surgery involved), and any genetic testing results for non-GHD indications.

Step 4: Document the functional impact. For adults, include quality of life assessment (QoL-AGHDA questionnaire is standard), body composition (DEXA showing fat/lean mass), and any bone density data. For children, document school performance, psychosocial impact, and physical limitations from short stature or the underlying condition.

Step 5: Submit Letter of Medical Necessity from an endocrinologist. Board-certified pediatric or adult endocrinologists carry the most weight in GH appeals. The letter must address: clinical diagnosis, stimulation test results, FDA-approved indication, and specific expected treatment benefits.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">external review. GH denials frequently cite internal criteria that are stricter than FDA labeling and Endocrine Society guidelines. External reviewers apply FDA indications and clinical guidelines — not plan-level restrictive policies. External reviews for GH are worth pursuing.

When Stimulation Testing Cannot Be Done Safely

Insulin tolerance testing (ITT) — considered the gold standard for GH stimulation — is contraindicated in patients with cardiovascular disease, seizure disorders, or severe cerebrovascular disease. If your plan requires ITT but it is medically contraindicated, document the contraindication explicitly and request that the glucagon stimulation test or GHRH-arginine test be accepted as alternatives per Endocrine Society guidelines.

Fight Back With ClaimBack

Growth hormone therapy requires meticulous documentation, but when properly assembled, the clinical case is compelling. ClaimBack helps you organize stimulation test data, growth velocity records, genetic testing, and the Endocrine Society guidelines into a complete appeal.

Start your growth hormone appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals